U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
109741109741Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid TumorsCompletedNo Results AvailableSolid TumorsDrug: Oprozomibhttps://ClinicalTrials.gov/show/NCT01129349
109742109742Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer PatientsCompletedHas ResultsFirst or Second Line HER2-negative Breast Cancer|Metastatic Disease Without Bone MetastasisDrug: Zoledronic acid|Drug: Standard Therapyhttps://ClinicalTrials.gov/show/NCT01129336
109743109743Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic AnemiaWithdrawnNo Results AvailableSevere Aplastic AnemiaDrug: Cyclophosphamide, Fludarabine, Rabbit ATGhttps://ClinicalTrials.gov/show/NCT01129323
109744109744First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.RecruitingNo Results AvailableGastrointestinal Neoplasm|Gastric AdenocarcinomaDrug: Irinotecan-Capecitabine-Oxaliplatinhttps://ClinicalTrials.gov/show/NCT01129310
109745109745A Biological Atlas of Severe Obesity (Biological Tissue Collection)RecruitingNo Results AvailableObesity|Glucose Intolerance|Diabeteshttps://ClinicalTrials.gov/show/NCT01129297
109746109746Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)CompletedHas ResultsTreatment Resistant Nephrotic SyndromeDrug: ACTHAR gelhttps://ClinicalTrials.gov/show/NCT01129284
109747109747Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy SubjectsCompletedNo Results AvailableHealthyDrug: clopidogrel|Drug: Matching placebohttps://ClinicalTrials.gov/show/NCT01129271
109748109748Multiple Dose Study of PF-04991532 in Patients With Type 2 DiabetesCompletedNo Results AvailableDiabetes Mellitus|Diabetes Mellitus, Type 2|Glucose Metabolism DisordersDrug: PF-04991532|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01129258
109749109749The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on OvulationCompletedHas ResultsOvulation|Luteal DevelopmentDrug: celebrex|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01129245
109750109750Diabetes Virus Detection Project, Intervention With GAD-alumRecruitingNo Results AvailableDiabetes, Type I|Enterovirus Infections|AutoimmunityDrug: GAD-alum|Other: Placebohttps://ClinicalTrials.gov/show/NCT01129232
109751109751Observation and Progressive Strength Training After Hip FractureActive, not recruitingNo Results AvailableExerciseOther: Strength traininghttps://ClinicalTrials.gov/show/NCT01129219
109752109752Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based TherapyActive, not recruitingNo Results AvailableAdenocarcinoma of the Esophagus|Adenocarcinomas of the Gastroesophageal Junction|Recurrent Esophageal Cancer|Squamous Cell Carcinoma of the Esophagus|Stage IV Esophageal CancerDrug: pralatrexate|Drug: docetaxel|Radiation: fludeoxyglucose F 18|Procedure: positron emission tomographyhttps://ClinicalTrials.gov/show/NCT01129206
109753109753AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaActive, not recruitingNo Results AvailableAdult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell LymphOther: Pharmacodynamic Studies|Other: Fatigue Inventory|Other: Pharmacogenomic studies|Drug: AR-42https://ClinicalTrials.gov/show/NCT01129193
109754109754Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell LymphomaCompletedNo Results AvailableAdult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Prolymphocytic Leukemia|Recurrent Adult Drug: azacitidine|Drug: bortezomib|Procedure: Correlative studieshttps://ClinicalTrials.gov/show/NCT01129180
109755109755Local Invasion of Pancreatic CancerRecruitingNo Results AvailablePancreatic Cancerhttps://ClinicalTrials.gov/show/NCT01129167
109756109756Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)RecruitingNo Results AvailableCarcinoma, Squamous CellDrug: infusions of Panitumumabhttps://ClinicalTrials.gov/show/NCT01129154
109757109757Telephone Tinnitus Education for Patients With Traumatic Brain Injury (TBI)Active, not recruitingNo Results AvailableTinnitusProcedure: Telephone Tinnitus Education|Procedure: Wait List Controlhttps://ClinicalTrials.gov/show/NCT01129141
109758109758Three Arm Trial of Immune Effects of EchinaceaCompletedHas ResultsUpper Respiratory Tract InfectionsBiological: Echinacea purpurea product|Biological: Echinacea purpurea product|Biological: Placebohttps://ClinicalTrials.gov/show/NCT01129128
109759109759Dose Response Study of Aerobic Exercise in Older AdultsCompletedNo Results AvailableAlzheimer's DiseaseBehavioral: Nonexercise control group|Behavioral: Aerobic Exercise Group 1|Behavioral: Aerobic Exercise Group 2|Behavioral: Aerobic Exercise Group 3https://ClinicalTrials.gov/show/NCT01129115
109760109760Efficacy and Safety Study of NPC-01 to Treat DysmenorrheaCompletedHas ResultsDysmenorrheaDrug: NPC-01|Drug: IKH-01|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01129102
109761109761Acceptability of Nutrient Supplements Among Women and Children in BangladeshCompletedNo Results AvailableMalnutritionDietary Supplement: Lipid-based nutrient supplement|Dietary Supplement: Lipid-based nutrient supplement|Dietary Supplement: Micronutrient powderhttps://ClinicalTrials.gov/show/NCT01129089
109762109762Perceptions of Thalassemia Major in Singapore: An Exploratory Study of StigmaCompletedNo Results AvailableThalassemia Majorhttps://ClinicalTrials.gov/show/NCT01129076
109763109763Pharmacokinetic Study of Single Doses of Clopidogrel, 75 mg and 300 mg, in Healthy SubjectsCompletedNo Results AvailableHealthyDrug: Clopidogrelhttps://ClinicalTrials.gov/show/NCT01129063
109764109764Effects of Omega-3 Fatty Acids on Markers of InflammationCompletedNo Results AvailableObesity|Hypertriglyceridemia|Insulin Resistance|HypertensionBehavioral: Fish Oil|Behavioral: Flax Seed Oilhttps://ClinicalTrials.gov/show/NCT01129050
109765109765Goal Directed Fluid Therapy in Free Flap Reconstructive SurgeryCompletedNo Results AvailableHead and Neck CancerOther: Goal directed fluid management based on continuous monitoring of stroke volumehttps://ClinicalTrials.gov/show/NCT01129037
109766109766An Open-label Safety Study of S-888711CompletedNo Results AvailableImmune ThrombocytopeniaDrug: 0.5 mg of S-888711https://ClinicalTrials.gov/show/NCT01129024
109767109767Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) NaproxenCompletedHas ResultsGastric UlcerDrug: PN400 (VIMOVO)|Drug: Naproxenhttps://ClinicalTrials.gov/show/NCT01129011
109768109768Sorafenib Plus S-1 in Advanced Solid TumorsActive, not recruitingNo Results AvailableAdvanced Solid TumorsDrug: Sorafenib|Drug: S-1https://ClinicalTrials.gov/show/NCT01128998
109769109769A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes MellitusCompletedNo Results AvailableDiabetes Mellitus, Type 2Drug: Canagliflozin 50 mg|Drug: Canagliflozin 100 mg|Drug: Canagliflozin 300 mg|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01128985
109770109770Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of Dental ErosionCompletedHas ResultsTooth ErosionDrug: Sodium fluoride|Drug: Sodium monoflurophosphate|Drug: Sterile waterhttps://ClinicalTrials.gov/show/NCT01128972

* Görseller ve İçerik tekif hakkına sahip olabilir